<b>Carvedilol Prevents Myocardial Fibrosis in Hamsters</b>

DOI Web Site 被引用文献1件 参考文献28件
  • Nanjo Shuji
    Division of Cardiovascular Medicine, Department of Internal Medicine, Ohmori Hospital. Toho University School of Medicine.
  • Yamazaki Junichi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Ohmori Hospital. Toho University School of Medicine.
  • Yoshikawa Kohki
    Department of Radiotechnical Sciences, Faculty of Radiological Health Sciences, Komazawa University
  • Ishii Toshiharu
    Second Department of Pathology, Toho University School of Medicine
  • Togane Yuko
    Division of Cardiovascular Medicine, Department of Internal Medicine, Ohmori Hospital. Toho University School of Medicine.

この論文をさがす

抄録

The objective of the present study was to determine if carvedilol protects against myocardial degeneration and fibrotic change, and reduces mortality in TO2 hamsters.<br> Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day. There were 15 TO2 hamsters in the carvedilol group (group C) and 10 in the untreated group (group N). The control group consisted of 11 Fb hamsters (group F). The mortality rate was determined from the number of surviving hamsters after 29 weeks. Myocardial fibrosis was evaluated by MRI and histopathological examination. EF and LVDd were determined by echocardiography at 8 and 29 weeks, while the MRI score was calculated at 29 weeks.<br> Mortality, histopathological fibrosis, and MRI score were all lower in group C than in group N. Carvedilol had a protective effect against myocardial fibrosis and decreased the mortality rate in TO2 hamsters. <br>

収録刊行物

  • International Heart Journal

    International Heart Journal 47 (4), 607-616, 2006

    一般社団法人 インターナショナル・ハート・ジャーナル刊行会

被引用文献 (1)*注記

もっと見る

参考文献 (28)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ